Inhibition of cytochrome P4502C9 activity in vitro by 5-hydroxytryptamine and adrenaline

被引:15
作者
Gervasini, G
Martínez, C
Agúndez, JAG
García-Gamito, FJ
Benítez, J
机构
[1] Univ Extremadura, Fac Med, Dept Farmacol, E-06071 Badajoz, Spain
[2] INSALUD Hosp Merida, Serv Gen Surg, Badajoz, Spain
来源
PHARMACOGENETICS | 2001年 / 11卷 / 01期
关键词
diclofenac; CYP2C9; microsomes;
D O I
10.1097/00008571-200102000-00004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In the present study, the occurrence of a modulatory effect of 14 neurotransmitters, precursors and metabolites on the cytochrome P450 2C9 (CYP2C9) enzyme activity, as determined by diclofenac 4-hydroxylation, was studied in human liver microsomes. Two indoleamines, 5-hydroxytryptamine (5-HT) and adrenaline, showed a non-competitive-type inhibitory effect of approximately 90% of the diclofenac 4-hydroxylase activity, with K-i values of 63.5 (0.7 and 156 (89.3 muM, respectively. The rest of substances analysed were weak inhibitors or had no inhibitory effect, CYP2C subfamily is present in human brain, although CYP2C9 isozyme has not yet been identified in this tissue, and CYP2C9 is involved in the metabolism of psychoactive drugs. Therefore, the fact that endogenous compounds could modulate the CYP2C9 activity, suggests that an hypothetical local activity of brain CYP2C9 might be susceptible to regulatory mechanisms. The possible clinical implications of this modulation are discussed. Pharmacogenetics 11:29-37 (C) Lippincott Williams & Wilkins.
引用
收藏
页码:29 / 37
页数:9
相关论文
共 60 条
[1]  
Agundez JAG, 1998, PHARMACOGENETICS, V8, P251
[2]  
AGURELL S, 1986, PHARMACOL REV, V38, P21
[3]   Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes [J].
Alkayed, NJ ;
Narayanan, J ;
Gebremedhin, D ;
Medhora, M ;
Roman, RJ ;
Harder, DR .
STROKE, 1996, 27 (05) :971-979
[4]   INVITRO INHIBITION STUDIES OF TOLBUTAMIDE HYDROXYLASE-ACTIVITY OF HUMAN-LIVER MICROSOMES BY AZOLES, SULFONAMIDES AND QUINOLINES [J].
BACK, DJ ;
TJIA, JF ;
KARBWANG, J ;
COLBERT, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 26 (01) :23-29
[5]   Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam [J].
Bonnabry, P ;
Leemann, T ;
Dayer, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 49 (04) :305-308
[6]  
BORNHEIM LM, 1992, DRUG METAB DISPOS, V20, P241
[7]  
Bourrie M, 1996, J PHARMACOL EXP THER, V277, P321
[8]   EFFECTS OF DISULFIRAM ON HEPATIC P450IIE1, OTHER MICROSOMAL-ENZYMES, AND HEPATOTOXICITY IN RATS [J].
BRADY, JF ;
XIAO, F ;
WANG, MH ;
LI, Y ;
NING, SM ;
GAPAC, JM ;
YANG, CS .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1991, 108 (02) :366-373
[9]   EFFECT OF QUINIDINE ON THE DEXTROMETHORPHAN O-DEMETHYLASE ACTIVITY OF MICROSOMAL FRACTIONS FROM HUMAN-LIVER [J].
BROLY, F ;
LIBERSA, C ;
LHERMITTE, M ;
BECHTEL, P ;
DUPUIS, B .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (01) :29-36
[10]   EVALUATION OF TRIACETYLOLEANDOMYCIN, ALPHA-NAPHTHOFLAVONE AND DIETHYLDITHIOCARBAMATE AS SELECTIVE CHEMICAL PROBES FOR INHIBITION OF HUMAN CYTOCHROMES P450 [J].
CHANG, TKH ;
GONZALEZ, FJ ;
WAXMAN, DJ .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 311 (02) :437-442